Joint Hypermobility, Autonomic Dysfunction, Gastrointestinal Dysfunction and Autoimmune markers (JAG-A): Clinical Associations and Response to Intravenous Immunoglobulin Therapy.


Journal

The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030

Informations de publication

Date de publication:
24 Jun 2024
Historique:
medline: 24 6 2024
pubmed: 24 6 2024
entrez: 24 6 2024
Statut: aheadofprint

Résumé

We examined autoimmunity markers (AIM) and autonomic dysfunction in patients with chronic neurogastroenterological symptoms and their relationship to joint hypermobility/hypermobility spectrum disorder (JH/HSD). AIM positivity was defined as a diagnosis of known autoimmune/autoinflammatory disorder (AIDX) with at least one positive seromarker of autoimmunity or at least two positive seromarkers by themselves. Three cohorts were studied: (a) Retrospective (n = 300); (b) Prospective validation cohort (n =133); and (c) Treatment cohort (n=40), administered open-label intravenous immunoglobulin (IVIG). AIM positivity was found in 40% and 29% of the retrospective and prospective cohorts, the majority of whom (71% and 69%, respectively) had AIDX. Significantly more patients with AIM had elevations of C-reactive protein (31% versus 15%, p<0.001) along with an increased proportion of cardiovascular autonomic dysfunction (48% versus 29%; p<.001), small fiber neuropathy (20% versus 9%; p=.002).8) and HLADQ8 positivity (24% versus 13%, p=.01). JH/HSD patients were more likely to have AIM (43% versus 15%, p=.001) along with more severe autonomic and gastrointestinal symptom scores. IVIG treatment was associated with robust improvement in pain, gastrointestinal and autonomic symptoms but adverse events were experienced by 62% patients. Autoimmune markers and autonomic dysfunction are common in patients with unexplained gastrointestinal symptoms, especially in those with JH/HSD. Many patients seem to respond to IVIG treatment but this needs to be confirmed by controlled trials. These results highlight the need for vigilance for autoimmune and autonomic factors and JH/HSD in patients with neurogastroenterological disorders. Clinicaltrials.gov, NCT04859829.

Identifiants

pubmed: 38912927
doi: 10.14309/ajg.0000000000002910
pii: 00000434-990000000-01204
doi:

Banques de données

ClinicalTrials.gov
['NCT04859829']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.

Auteurs

Pankaj J Pasricha (PJ)

Mayo Clinic, Scottsdale, AZ, USA.

Megan McKnight (M)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Luisa Villatoro (L)

Mayo Clinic, Scottsdale, AZ, USA.

Guillermo Barahona (G)

Mayo Clinic, Scottsdale, AZ, USA.

Jeffrey Brinker (J)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Ken Hui (K)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Michael Polydefkis (M)

Mayo Clinic, Scottsdale, AZ, USA.

Robert Burns (R)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Zsuzsanna H McMahan (ZH)

Univeristy of Texas Health Science Center, Houston, TX, USA.

Neda Gould (N)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Brent Goodman (B)

Mayo Clinic, Scottsdale, AZ, USA.

Joseph Hentz (J)

Mayo Clinic, Scottsdale, AZ, USA.

Glenn Treisman (G)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Classifications MeSH